BioCentury | Jun 5, 2020
Emerging Company Profile

Epsilogen: co-opting IgE antibodies against cancer

Epsilogen is taking a long overlooked isotype of human antibodies -- the IgE class -- and leveraging their high affinity for immune effector cells to seek out and destroy solid tumors. “What we are doing...
BioCentury | Oct 18, 2018
Distillery Techniques

Assays and screens

...and magnetic beads conjugated to VAR2CSA into a microfluidic system, where the beads bind oncofetal chondroitin sulfate proteoglycans...
BioCentury | Aug 20, 2018
Preclinical News

Malaria protein helps detect circulating tumor cells

...recombinant variant surface antigen 2 chondroitin sulphate A (VAR2CSA) malaria protein selectively binds to oncofetal chondroitin sulfate proteoglycans (CSPG)...
...VAR2 and VarCT, told BioCentury the parent company is selecting a lead therapeutic targeting oncofetal CSPG...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample, cell culture and mouse studies suggest CAR T cells targeting MCSP could help treat glioblastoma. In tumor samples from patients, high MCSP expression was correlated with poor overall survival. In...
BioCentury | Mar 29, 2018
Translation in Brief

Putting GBM in Check

A new target added to the mix of glioblastoma CAR T antigens, MCSP, checks all of the boxes of a good cell therapy for solid tumors, according to a study in Science Translational Medicine . Identifying...
BioCentury | Feb 28, 2018
Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Detection of a panel of circulating tumor cell (CTC)-derived RNA transcripts in blood could help predict survival and disease progression in metastatic melanoma patients receiving immune checkpoint inhibitors. The method scores blood...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: Chondroitin sulfate proteoglycans (CSPG); versican (VCAN)

...disease INDICATION: Multiple sclerosis (MS) In vitro and mouse studies identified a UDP-N-acetylglucosamine-based inhibitor of CSPG...
...testing in mouse and human astrocyte-based assays of CSPG synthesis identified a compound that decreased CSPG...
...compound. In mice with lysolecithin-induced spinal cord demyelination, the compound decreased injury-induced up-regulation of the CSPG...
BioCentury | Apr 7, 2016
Product R&D

Branching out

With its second compound about to hit the clinic and a fresh influx of money, Symic Biomedical Inc. is lining up the next three preclinical programs for its extracellular matrix (ECM)-targeting technology. By applying each...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Variant surface antigen 2 chondroitin sulphate A (VAR2CSA); chondroitin sulfate proteoglycans (CSPG)

...epithelial cancers, bone sarcomas or soft tissue sarcomas, binding between VAR2CSA and its target, placental-like CSPG...
...antigen receptor (CAR) T cells. TARGET/MARKER/PATHWAY: Variant surface antigen 2 chondroitin sulphate A (VAR2CSA) ; chondroitin sulfate proteoglycans (CSPG)...
BioCentury | Dec 11, 2014
Targets & Mechanisms

PIEZO de resistance

A pair of recently identified calcium channels- PIEZO1 and PIEZO2-control the response of cartilage to heavy loads and offer new targets for joint injury and osteoarthritis, according to findings from a team at Duke University...
Items per page:
1 - 10 of 27